Home / Market News / $CSTL

$CSTL news and market catalysts

The 15 most recent market catalysts affecting $CSTL, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

15 catalysts 2 high impact 9 bullish 2 bearish Biotechnology
Nov 11, 2026 Corporate Catalyst Neutral Impact 55
Castle Biosciences Announces New Data Presentations for DecisionDx-Melanoma
Castle Biosciences announced upcoming presentations of new data for its DecisionDx-Melanoma test at two medical conferences in November 2026. This matters because the data aims to …
Nov 9, 2026 Corporate Catalyst Bullish Impact 65
Baird Raises Price Target for Castle Biosciences
Baird has raised its price target for Castle Biosciences (CSTL) to $41 from $39. This adjustment stems from the company's recently reported strong third-quarter test volumes and up…
Nov 7, 2026 Corporate Catalyst Bullish Impact 60
Keybanc Maintains Overweight Rating and Raises Price Target for Castle Biosciences
Keybanc maintained its 'Overweight' rating on Castle Biosciences and raised its price target to $40 from $35. This analyst upgrade signals increased confidence in the molecular dia…
Nov 5, 2026 Corporate Catalyst Bullish Impact 75
Castle Biosciences Reports Third Quarter 2026 Financial Results and Raises Annual Revenue Guidance
Castle Biosciences announced Q3 2026 revenue of $102.9 million, a 24% increase year-over-year, which is a significant beat. This strong performance prompted the company to raise it…
Oct 29, 2026 Corporate Catalyst Neutral Impact 65
Mizuho Initiates Coverage of Castle Biosciences with Outperform Rating
Mizuho Securities has initiated coverage on Castle Biosciences with an 'Outperform' rating, indicating a positive outlook from a significant financial institution. This analyst act…
Oct 12, 2026 Corporate Catalyst Neutral Impact 55
Castle Biosciences To Present New Data From Three Studies Evaluating Its TissueCypher Barrett's Esophagus Test At ACG 2026 Annual Scientific Meeting And Postgraduate Course
Castle Biosciences is announcing the presentation of new data for its TissueCypher Barrett's Esophagus test at a significant medical conference (ACG 2026). This matters because pos…
Sep 24, 2026 Corporate Catalyst Bearish Impact 55
Castle Biosciences Announces Publication Of New Study Highlighting Demand For Molecular Testing In Atopic Dermatitis
Castle Biosciences announced the publication of a study that highlights the challenges patients with atopic dermatitis face in achieving treatment goals and their strong interest i…
Sep 22, 2026 Corporate Catalyst Bullish Impact 55
Castle Biosciences Announces Opening Of New Laboratory And Office Facility In Scottsdale, Arizona
Castle Biosciences (CSTL) has opened a new, larger facility in Scottsdale, Arizona. This move signifies the company's operational expansion to accommodate increasing demand for its…
Sep 15, 2026 Corporate Catalyst Bullish Impact 75
Castle Biosciences Says 699-Patient Decision Modeling Study Shows TissueCypher Would Raise Appropriate Barrett's Esophagus Management From 59.8% To 75.3%; Escalation In Non-Dysplastic Progressors From 30.4% To 56.9%
The study results for TissueCypher are a strong positive catalyst for Castle Biosciences. By demonstrating a significant improvement in appropriate patient management and the ident…
Aug 17, 2026 Corporate Catalyst Neutral Impact 55
Castle Biosciences Approved For Dual Listing On Nasdaq Texas While Maintaining Primary Listing On Nasdaq Global Market
This dual listing is a positive development for Castle Biosciences (CSTL) as it broadens its investor base and potentially improves trading liquidity by accessing a new exchange. W…
Aug 3, 2026 Corporate Catalyst Bullish Impact 55
BTIG Maintains Buy on Castle Biosciences, Raises Price Target to $44
BTIG analyst Mark Massaro maintained a 'Buy' rating on Castle Biosciences (CSTL) and raised the price target from $40 to $44. This action signals continued confidence in the compan…
Jul 30, 2026 Corporate Catalyst Bullish Impact 85
Castle Biosciences shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY2026 sales guidance above estimates.
This headline signals a strong positive corporate catalyst for Castle Biosciences. Better-than-expected earnings and an upward revision of future sales guidance demonstrate operati…
Jul 30, 2026 Corporate Catalyst Bullish Impact 75
Castle Biosciences Raises FY2026 Sales Guidance from $345.000M-$355.000M to $365.000M-$375.000M vs $352.291M Est
Castle Biosciences (CSTL) has filed an 8-K to announce an upward revision to its fiscal year 2026 sales guidance. The company now expects sales to be between $365 million and $375 …
Jul 30, 2026 Corporate Catalyst Bearish Impact 92
Castle Biosciences Q2 Adj. EPS $(0.07) Beats $(0.41) Estimate, Sales $103.546M Beat $86.240M Estimate
Castle Biosciences (CSTL) announced Q2 results that significantly exceeded analyst expectations. The company reported a loss of $(0.07) per share, beating the $(0.41) estimate, and…
Jul 14, 2026 Corporate Catalyst Bullish Impact 75
Castle Biosciences Receives Approval For AdvanceAD-Tx Test From New York State Department Of Health
The approval of the AdvanceAD-Tx test by the New York State Department of Health is a significant positive catalyst for Castle Biosciences (CSTL). It opens up a major market for th…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.